Riedel M - Search Results

1

[Schizophrenic patients in the family practice].

Riedel M, Spellmann I, Müller N, Möller HJ. Riedel M, et al. MMW Fortschr Med. 2007 May 21;149 Suppl 2:98-101. MMW Fortschr Med. 2007. PMID: 17724979 Review. German.

2

Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia.

Müller N, Riedel M, Scheppach C, Brandstätter B, Sokullu S, Krampe K, Ulmschneider M, Engel RR, Möller HJ, Schwarz MJ. Müller N, et al. Among authors: riedel m. Am J Psychiatry. 2002 Jun;159(6):1029-34. doi: 10.1176/appi.ajp.159.6.1029. Am J Psychiatry. 2002. PMID: 12042193 Clinical Trial.

3

No association between the G308A polymorphism of the tumor necrosis factor-alpha gene and schizophrenia.

Riedel M, Krönig H, Schwarz MJ, Engel RR, Kühn KU, Sikorski C, Sokullu S, Ackenheil M, Möller HJ, Müller N. Riedel M, et al. Eur Arch Psychiatry Clin Neurosci. 2002 Oct;252(5):232-4. doi: 10.1007/s00406-002-0386-1. Eur Arch Psychiatry Clin Neurosci. 2002. PMID: 12451465

4

[Fewer adverse effects! Treatment with atypical neuroleptics].

Müller N, Riedel M. Müller N, et al. Among authors: riedel m. Pharm Unserer Zeit. 2002;31(6):558-65. doi: 10.1002/1615-1003(200211)31:6<558::AID-PAUZ558>3.0.CO;2-Y. Pharm Unserer Zeit. 2002. PMID: 12481513 Review. German. No abstract available.

5

Comorbidity of Tourette's syndrome and schizophrenia--biological and physiological parallels.

Müller N, Riedel M, Zawta P, Günther W, Straube A. Müller N, et al. Among authors: riedel m. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Dec;26(7-8):1245-52. doi: 10.1016/s0278-5846(02)00260-9. Prog Neuropsychopharmacol Biol Psychiatry. 2002. PMID: 12502010

6

Serotonergic dysfunction in schizophrenia assessed by the loudness dependence measure of primary auditory cortex evoked activity.

Juckel G, Gallinat J, Riedel M, Sokullu S, Schulz C, Möller HJ, Müller N, Hegerl U. Juckel G, et al. Among authors: riedel m. Schizophr Res. 2003 Nov 15;64(2-3):115-24. doi: 10.1016/s0920-9964(03)00016-1. Schizophr Res. 2003. PMID: 14613676 Clinical Trial.

7

Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder.

Pogarell O, Hamann C, Pöpperl G, Juckel G, Choukèr M, Zaudig M, Riedel M, Möller HJ, Hegerl U, Tatsch K. Pogarell O, et al. Among authors: riedel m. Biol Psychiatry. 2003 Dec 15;54(12):1406-13. doi: 10.1016/s0006-3223(03)00183-5. Biol Psychiatry. 2003. PMID: 14675805

8

COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy.

Müller N, Ulmschneider M, Scheppach C, Schwarz MJ, Ackenheil M, Möller HJ, Gruber R, Riedel M. Müller N, et al. Among authors: riedel m. Eur Arch Psychiatry Clin Neurosci. 2004 Feb;254(1):14-22. doi: 10.1007/s00406-004-0478-1. Eur Arch Psychiatry Clin Neurosci. 2004. PMID: 14991374 Clinical Trial.

9

COX-2 inhibitors as adjunctive therapy in schizophrenia.

Müller N, Strassnig M, Schwarz MJ, Ulmschneider M, Riedel M. Müller N, et al. Among authors: riedel m. Expert Opin Investig Drugs. 2004 Aug;13(8):1033-44. doi: 10.1517/13543784.13.8.1033. Expert Opin Investig Drugs. 2004. PMID: 15268640 Review.

10

Serotonin and dopamine transporter availabilities correlate with the loudness dependence of auditory evoked potentials in patients with obsessive-compulsive disorder.

Pogarell O, Tatsch K, Juckel G, Hamann C, Mulert C, Pöpperl G, Folkerts M, Choukèr M, Riedel M, Zaudig M, Möller HJ, Hegerl U. Pogarell O, et al. Among authors: riedel m. Neuropsychopharmacology. 2004 Oct;29(10):1910-7. doi: 10.1038/sj.npp.1300537. Neuropsychopharmacology. 2004. PMID: 15292904

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

617 results

Search Page

Filters